Therapeutic Targets in Advanced Penile Cancer: From Bench to Bedside.
Lance C PagliaroBurak TekinSounak GuptaLoren P Herrera HernandezPublished in: Cancers (2024)
Discovery of effective systemic therapies for patients with advanced penile cancer has been slow to occur. Comprehensive genomic profiling from several studies shed light on the molecular oncogenesis of penile squamous cell carcinoma (PSCC) and differences between HPV-related and unrelated tumors. While these two subsets of PSCC appear distinct in their biology, there are not yet specific treatment strategies recommended on that basis. Cell surface proteins have been identified that may potentially serve as drug targets for monoclonal antibodies or small molecule inhibitors. Here, we review some of the new biological insights regarding PSCC that could lead to improved therapies, as well as the related clinical trials recently completed or in progress. We conclude that antibody-drug conjugates are especially promising, as are the combinations of immune checkpoint inhibitors with other types of drugs.
Keyphrases
- small molecule
- papillary thyroid
- squamous cell carcinoma
- clinical trial
- cell surface
- squamous cell
- lymph node metastasis
- protein protein
- drug induced
- prostate cancer
- emergency department
- high grade
- high throughput
- radiation therapy
- single cell
- peripheral blood
- childhood cancer
- cord blood
- cancer therapy
- genome wide
- rectal cancer
- genome wide analysis